Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11294202 | 0.83 | TSHR (0.42) | TSHRTDP1LMNAL3MBTL1KDM4E | |
| SCHEMBL16074683 | 0.83 | TSHR (0.48) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL444372 | 0.82 | TSHR (0.46) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL18937201 | 0.82 | TSHR (0.46) | TSHRTDP1LMNAL3MBTL1TRPA1 | |
| SCHEMBL4154359 | 0.81 | TSHR (0.46) | TSHRTDP1LMNATRPA1ALDH1A1 | |
| SCHEMBL9092832 | 0.79 | TDP1 (0.53) | TSHRTDP1LMNAL3MBTL1KDM4E | |
| SCHEMBL9095491 | 0.79 | TDP1 (0.53) | TSHRTDP1LMNAL3MBTL1KDM4E | |
| SCHEMBL14319836 | 0.79 | TDP1 (0.53) | TSHRTDP1LMNAL3MBTL1KDM4E | |
| SCHEMBL9740003 | 0.79 | TSHR (0.47) | TSHRTDP1LMNAL3MBTL1KDM4E | |
| SCHEMBL6225317 | 0.79 | TDP1 (0.53) | TSHRTDP1LMNAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-4731392-A | Process for the preparation of polyester polyols, based on 2-methyl-1,4-butanediol, which are liquid at room temperature, and their use for the preparation of plastic materials | BASF AKTIENGESELLSCHAFT (DE) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | TSHR 737/4885TDP1 4738/4885LMNA 3635/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | TSHR 737/4885TDP1 4738/4885LMNA 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.